In a report released yesterday, Arlinda Lee from Canaccord Genuity maintained a Buy rating on Zymeworks Inc (NYSE: ZYME), with a price target of $21. The company’s shares closed yesterday at $18.97.
According to TipRanks.com, Lee is a 4-star analyst with an average return of 7.0% and a 47.4% success rate. Lee covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Aquinox Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Zymeworks Inc is Strong Buy and the average price target is $24.50, representing a 29.2% upside.
In a report issued on June 4, Wells Fargo also reiterated a Buy rating on the stock with a $37 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29 and a one-year low of $6.25. Currently, Zymeworks Inc has an average volume of 101.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that can two non-overlapping epitopes.
